Robert Parson has over 15 years of experience in leadership roles in the healthcare industry. He has a proven track record of guiding medical products from concept to commercialization and ensuring quality and regulatory compliance. Parson has expertise in areas such as strategic planning, regulatory affairs, clinical research, and pharmacoeconomics. He holds advanced degrees from the University of California San Diego, Rochester Institute of Technology, and Purdue University.
This document provides a summary of Darral Addison's qualifications and experience. It includes over 20 years of experience in clinical, pharmaceutical, biotech, medical device, food and IT industries, with strong communication and regulatory skills. Addison has held roles at various companies focused on quality assurance, validation, clinical trials, and project management. He has a background in chemistry and quality systems with various industry certifications and a master's degree.
ExL Pharma Clinical Trials Phase I and Phase IIa Conference Brochure: Phase 1...bryonmain
油
There is a pill or treatment for almost everything, or at least, that is how it seems. However, the amount of effort that goes into a pill or treatment before it is launched is extensive, expensive and often inefficient.
Efficiency and innovation go hand-in-hand with R&D and the development of clinical trials, however, FDA regulations and clinical trial standardization end up stifling these two key factors. This leads to drawn out processes that cost companies hundreds of millions of dollars before the drugs hit the market. Efforts have been made to increase efficiency in phase I/IIA with some companies changing their clinical trial manifestos to suit the available patient population at clinical sites, but more emphasis should be placed on creating more efficient processes for first in human studies by optimizing pharmacokinetics/pharmacodynamics, dosage selection, technological advancements to improve efficacy and structured patient mapping to increase successful trial and patient recruitment opportunities.
This program will give delegates the opportunity to share proven strategies between companies to help increase efficiency in this space and streamline processes to cut down costs. This event will bring together large and small companies and experts in this space to share best practices to decrease the financial drain theses phases have on the overall clinical trial budget. Life science corporations need the most up-to-date tools and practices to increase success by streamlining processes, sharing successful biomarker strategies, anticipating dosing quantities, and optimizing healthy or specialty patient recruitment and retention. Current strategies include patient mapping before organizing and setting up a clinical space, tailoring early phase clinical trials to patient populations, purchasing biological samples from collection companies, and trying to accelerate the process by submitting for breakthrough therapy designation.
Top Reasons To Attend
Identify Compound Development Strategies to Optimize Success in Clinical Trials
Learn Best Practices for Early Decision-Making Through Analysis of Biomarker Utility in Drug Development
Utilize Analytical Technology to Evaluate Multiple Configurations of a Small Molecule to Increase the Feasibility of Drug in Clinical Trials
Implement Adaptive Design in Proof of Concept Studies to Increase Efficiency, Decrease Time and Decrease Overall Cost
Explore the Seamless Development of Phase I to Phase II in Clinical Trials
NINE Case Studies and a Panel Session on Early Phase Clinical Trial Strategies
Repurposing in the Chaos of 2020 and Validity of Scientific EvidenceAjaz Hussain
油
Having been focused on manufacturing challenges for most of 2020, taking a time out to think about how best to garner "new prior knowledge" needed to facilitate development of evidence for repurposing option for the SARS-COV-2 cases and COVID-19 disease.
Data Integrity Validation Keynote Address Boston August 2016Ajaz Hussain
油
The document provides an overview of a keynote presentation on data integrity and compliance. It discusses evaluating the global regulatory landscape on data integrity expectations, the 2016 FDA draft guidance on data integrity, and overcoming top challenges. It also addresses proactively assuring data integrity and achieving an effective culture of pharmaceutical quality. The presentation examines increasing breaches of data integrity noted in FDA warning letters and inspections globally.
Gina Diguglielmo has over 30 years of experience in clinical research and operations management. She has managed budgets up to $10 million and trials with over 1,300 patients. As an independent consultant, she provides expertise in areas such as project management, budgeting, and process improvement. Previously, she held director-level positions at Novartis and other large pharmaceutical companies where she led global process improvement initiatives reducing time and costs.
Martha Schmidt has over 20 years of experience in clinical research, drug development, and the medical field. She has worked for several large pharmaceutical companies, managing clinical trials and ensuring regulatory compliance. She is knowledgeable about all phases of drug development and has experience in clinical oncology. Schmidt has extensive expertise in clinical data review and analysis. She is passionate about assisting with product liability and medical malpractice litigation through case review and serving as an expert witness.
This is a summary of Karen Knight's resume:
Karen Knight has over 33 years of experience in healthcare, including roles as a clinical RN, perioperative manager, healthcare educator, and construction project manager. She has extensive experience managing multi-disciplinary healthcare teams and optimizing technology and workflows. Her most recent role was as Project Manager for the construction of a new 112-bed hospital, which was completed on time and under budget.
IMS Health Real-World Evidence Solutions at ISPOR November 2015IMSHealthRWES
油
Welcome to the IMS Health Real-World Evidence (RWE) Solutions program of activities at the forthcoming ISPOR 18th Annual European Congress in Milan. We invite you to join us at more than 70 presentations that spotlight exciting innovations and applications of outcomes research and RWE. And please visit us at our booth to learn more about our pioneering efforts including the e360TM technology suite, RWD Catalogue with 1,800+ data sources identified, and the newly launched RWE Dictionary. Full details of our ISPOR schedule can be found in the brochure.
IMS Health Enriched Real-World Data StudyIMSHealthRWES
油
1) Researchers developed the DIAREG registry in Germany using a mixed methods approach to overcome limitations of electronic medical record databases which often lack critical variables.
2) The registry links retrospective data from electronic medical records with prospective clinical data collected through electronic case report forms and patient-reported outcomes to create a rich data resource.
3) As of September 2014, the DIAREG registry contained data on 1,071 diabetes patients in Germany, enabling granular observational research on relationships and outcomes that were previously difficult to study.
Strategies for Growth and Survival of Pathology DepartmentsHidee Cyd
油
This document discusses strategies for survival and growth in pathology and laboratory medicine. It describes consolidation of laboratories across institutions to reduce costs, automation to increase efficiency and capacity, specialization to improve quality, and quality management to enhance decision making. The focus is on the consolidation of multiple New York City public hospital laboratories under one network with the Bellevue laboratory as the central referral site. This consolidation improved productivity, standardized operations, and reduced costs through economies of scale. Automation was also used to increase efficiency by reducing manual processes and errors while improving turnaround times.
Do you know how many rewarding job opportunities exist in the Clinical resea...Access-Pharma Jobs
油
If you are a BSc/MSc/PhD or MD/PharmD in career change, you can see some of the available career opportunities in the Clinical research industry and how to get in this field in this presentation made on Jan 14, 2017 at the Pharmacolloque 2017:
https://cra-school.com/news/
Need for an Integrated approach to Formulation Research and Knowledge ManagementAjaz Hussain
油
1. Confidence in Generics: Need for an Integrated
approach to Formulation Research and Knowledge
Management (Ajaz Hussain)
2. Mechanism for an integrated approach to Formulation
Research, Knowledge Management, & Knowledge
sharing with FDA & Industry (Steve Byrn)
3. Integrated approach for evolving standards for
formulation design - case example NTI's (Ken Morris)
4. Integrated approach for evolving standard for analytical
characterization - case example excipient variability
(Eric Munson)
This document provides a summary of Maria Bloodgood's professional experience and qualifications. She has over 20 years of experience in project management roles in the pharmaceutical industry, focusing on clinical development and medical affairs. Her most recent role is as a Global Project Manager at Eurofins Central Laboratory, where she is responsible for managing projects and ensuring they are completed on time, on budget, and meeting quality standards. She has extensive experience managing clinical studies and programs across multiple therapeutic areas.
Immuron Limited is a clinical-stage biopharmaceutical company targeting inflammatory and infectious diseases with oral immunotherapies. It has two lead clinical assets in Phase 2 development for fatty liver disease and C. difficile infection. It also has a registered and revenue-generating Travelan product targeting traveler's diarrhea. The company is listed on the NASDAQ and ASX exchanges and has an experienced management team supported by key opinion leaders. It is well positioned to address significant unmet needs in liver disease and infectious disease markets with blockbuster potential. Near-term milestones include interim data readouts from multiple Phase 2 NASH and pediatric NAFLD trials in 2017-2018.
The document discusses strategies for successful global drug development. It focuses on navigating FDA accelerated approval programs, new frontiers in personalized medicine, and evolving regulatory paradigms for digital health. The presentation provides an overview of key FDA expedited programs like fast track designation and breakthrough therapy designation. It also examines how regulators are adapting approaches to personalized medicine and digital health technologies.
Shannon Johnson has extensive experience in automation engineering and developing automated assays. She currently works as an automation engineer at Monsanto where she programs automation platforms, develops new assays, and trains colleagues. Previously she worked at Pfizer developing in vitro ADME assays using automation and held a laboratory assistant role conducting agricultural testing. She has a B.S. in Biology and Chemistry and certification in Broad Field Science.
Real-world patients have an average of 6 serious co-morbid conditions & take 10 medications
*Complicated patients are invariably excluded from clinical research studies, making it impossible to know what treatments work best
This document is a resume for Donna M. Carr, who has over 15 years of experience as a pharmaceutical scientist specializing in assay development and execution to support drug discovery and development programs in oncology and infectious diseases. Her skills include biochemical and cellular assays, automation, data analysis, and project management. She has authored numerous publications, reports, standard operating procedures, and patent applications. She is recognized as a strong collaborator and effective communicator who has supported projects from hit identification through clinical trials.
Shamisha Learning Center, Ahmedabad, Gujarat, India-Specialized Training, Workshops and courses on Quality, Regulatory, R & D, Supply Chain and Manufacturing
Gagan Kaur is seeking an in-house clinical research position utilizing her almost 2 years of CRO experience and 4 years of pharmaceutical experience. She has a strong technical background in clinical trials, drug development, virology, and GCP guidelines. Currently she works as a Central Monitoring Associate at INC Research, where she is responsible for remote monitoring, site management, and ensuring compliance. Previously she has held positions in medical operations and quality control.
This presentation discusses ethical capacity building at various levels - individual, organizational, industry, regulatory, and country. It provides examples of data integrity issues found during FDA inspections of Indian pharmaceutical companies. It emphasizes the need for ethical leadership and culture at all levels to ensure data integrity and protect patient safety.
Critical Path Initiative Challenges: FDA ACPS Meeting 19 October 2004Ajaz Hussain
油
Each section within P2 can have an impact on the other P2 sections and similarly other sections of a submission and to CGMPs By recognizing this as a complex design system that involves multiple attributes, goals, constraints, multidisciplinary design teams (subsystems), different degrees of uncertainty, risk tolerance, etc., we wish to find opportunities to identify robust designs and design space that provides a sound basis for risk assessment and mitigation
Behavioral Economics and Managment of Pharmaceutical QbD 25 August 2016Ajaz Hussain
油
Pharmaceutical knowledge pyramid can be toppled easily!
Serendipitous intersection of Behavioral Economics & CGMP.
Why attention to Behavioral Economics can improve management of QbD work-streams?
How? What (benefits)?
Between regulatory query and response there is Design Space. In that space is our comparability protocol
Real world evidence pharmaceutical industry-plPeter Le
油
This document discusses the challenges and opportunities of real-world evidence (RWE) in the pharmaceutical industry. It notes that while RWE from real-world data can help improve drug development, operations, and decision-making, there are also challenges to overcome. These include issues with data accessibility, analysis capacity, and balancing limited resources. However, RWE also presents opportunities to increase value, understand effectiveness beyond clinical trials, and gain business insights. Overall, RWE brings significant opportunities if pharmaceutical companies can address solvable challenges through leadership, governance, and transformation.
The document provides an overview of clinical study protocols, including their purpose, key components, and importance. It describes the various sections of a protocol, such as the background and objectives, study design, subject selection criteria, study procedures, safety and efficacy assessments, and data handling. Maintaining adherence to the protocol is important to ensure the safety of participants and integrity of the clinical trial.
Setting up of new pharmacovigilance centresPriti Gupta
油
Cure & Care Pharma proposes establishing a Pharmacovigilance Centre to monitor drug safety. The centre would be approved by regulatory authorities and function to collect, analyze and communicate information about adverse drug reactions and risks. The proposal outlines the need for pharmacovigilance due to increasing drug availability and irrational practices. It describes the centre's scope, reporting processes, infrastructure needs and budget to effectively oversee post-marketing drug safety.
Walter King is a seasoned senior R&D executive with over 30 years of experience in medical device and diagnostic product development. He has a proven track record of successfully directing projects from research through product launch on time and on budget. Key accomplishments include overseeing development of personalized diagnostic tests and medical devices that were paramount in the sale of two companies. He possesses strong leadership skills and experience managing multi-disciplinary teams across major companies.
Delivering real world evidence to demonstrate product safety and valueKishan Patel, MBA
油
This document discusses how observational research and patient registries can provide real-world evidence on product safety and effectiveness. It outlines Quintiles' capabilities in this area, including experience conducting 195 patient registries and observational studies involving over 9 million patients. Quintiles claims it can help companies demonstrate products' performance in various populations and support regulatory and coverage decisions through generating real-world evidence.
IMS Health Enriched Real-World Data StudyIMSHealthRWES
油
1) Researchers developed the DIAREG registry in Germany using a mixed methods approach to overcome limitations of electronic medical record databases which often lack critical variables.
2) The registry links retrospective data from electronic medical records with prospective clinical data collected through electronic case report forms and patient-reported outcomes to create a rich data resource.
3) As of September 2014, the DIAREG registry contained data on 1,071 diabetes patients in Germany, enabling granular observational research on relationships and outcomes that were previously difficult to study.
Strategies for Growth and Survival of Pathology DepartmentsHidee Cyd
油
This document discusses strategies for survival and growth in pathology and laboratory medicine. It describes consolidation of laboratories across institutions to reduce costs, automation to increase efficiency and capacity, specialization to improve quality, and quality management to enhance decision making. The focus is on the consolidation of multiple New York City public hospital laboratories under one network with the Bellevue laboratory as the central referral site. This consolidation improved productivity, standardized operations, and reduced costs through economies of scale. Automation was also used to increase efficiency by reducing manual processes and errors while improving turnaround times.
Do you know how many rewarding job opportunities exist in the Clinical resea...Access-Pharma Jobs
油
If you are a BSc/MSc/PhD or MD/PharmD in career change, you can see some of the available career opportunities in the Clinical research industry and how to get in this field in this presentation made on Jan 14, 2017 at the Pharmacolloque 2017:
https://cra-school.com/news/
Need for an Integrated approach to Formulation Research and Knowledge ManagementAjaz Hussain
油
1. Confidence in Generics: Need for an Integrated
approach to Formulation Research and Knowledge
Management (Ajaz Hussain)
2. Mechanism for an integrated approach to Formulation
Research, Knowledge Management, & Knowledge
sharing with FDA & Industry (Steve Byrn)
3. Integrated approach for evolving standards for
formulation design - case example NTI's (Ken Morris)
4. Integrated approach for evolving standard for analytical
characterization - case example excipient variability
(Eric Munson)
This document provides a summary of Maria Bloodgood's professional experience and qualifications. She has over 20 years of experience in project management roles in the pharmaceutical industry, focusing on clinical development and medical affairs. Her most recent role is as a Global Project Manager at Eurofins Central Laboratory, where she is responsible for managing projects and ensuring they are completed on time, on budget, and meeting quality standards. She has extensive experience managing clinical studies and programs across multiple therapeutic areas.
Immuron Limited is a clinical-stage biopharmaceutical company targeting inflammatory and infectious diseases with oral immunotherapies. It has two lead clinical assets in Phase 2 development for fatty liver disease and C. difficile infection. It also has a registered and revenue-generating Travelan product targeting traveler's diarrhea. The company is listed on the NASDAQ and ASX exchanges and has an experienced management team supported by key opinion leaders. It is well positioned to address significant unmet needs in liver disease and infectious disease markets with blockbuster potential. Near-term milestones include interim data readouts from multiple Phase 2 NASH and pediatric NAFLD trials in 2017-2018.
The document discusses strategies for successful global drug development. It focuses on navigating FDA accelerated approval programs, new frontiers in personalized medicine, and evolving regulatory paradigms for digital health. The presentation provides an overview of key FDA expedited programs like fast track designation and breakthrough therapy designation. It also examines how regulators are adapting approaches to personalized medicine and digital health technologies.
Shannon Johnson has extensive experience in automation engineering and developing automated assays. She currently works as an automation engineer at Monsanto where she programs automation platforms, develops new assays, and trains colleagues. Previously she worked at Pfizer developing in vitro ADME assays using automation and held a laboratory assistant role conducting agricultural testing. She has a B.S. in Biology and Chemistry and certification in Broad Field Science.
Real-world patients have an average of 6 serious co-morbid conditions & take 10 medications
*Complicated patients are invariably excluded from clinical research studies, making it impossible to know what treatments work best
This document is a resume for Donna M. Carr, who has over 15 years of experience as a pharmaceutical scientist specializing in assay development and execution to support drug discovery and development programs in oncology and infectious diseases. Her skills include biochemical and cellular assays, automation, data analysis, and project management. She has authored numerous publications, reports, standard operating procedures, and patent applications. She is recognized as a strong collaborator and effective communicator who has supported projects from hit identification through clinical trials.
Shamisha Learning Center, Ahmedabad, Gujarat, India-Specialized Training, Workshops and courses on Quality, Regulatory, R & D, Supply Chain and Manufacturing
Gagan Kaur is seeking an in-house clinical research position utilizing her almost 2 years of CRO experience and 4 years of pharmaceutical experience. She has a strong technical background in clinical trials, drug development, virology, and GCP guidelines. Currently she works as a Central Monitoring Associate at INC Research, where she is responsible for remote monitoring, site management, and ensuring compliance. Previously she has held positions in medical operations and quality control.
This presentation discusses ethical capacity building at various levels - individual, organizational, industry, regulatory, and country. It provides examples of data integrity issues found during FDA inspections of Indian pharmaceutical companies. It emphasizes the need for ethical leadership and culture at all levels to ensure data integrity and protect patient safety.
Critical Path Initiative Challenges: FDA ACPS Meeting 19 October 2004Ajaz Hussain
油
Each section within P2 can have an impact on the other P2 sections and similarly other sections of a submission and to CGMPs By recognizing this as a complex design system that involves multiple attributes, goals, constraints, multidisciplinary design teams (subsystems), different degrees of uncertainty, risk tolerance, etc., we wish to find opportunities to identify robust designs and design space that provides a sound basis for risk assessment and mitigation
Behavioral Economics and Managment of Pharmaceutical QbD 25 August 2016Ajaz Hussain
油
Pharmaceutical knowledge pyramid can be toppled easily!
Serendipitous intersection of Behavioral Economics & CGMP.
Why attention to Behavioral Economics can improve management of QbD work-streams?
How? What (benefits)?
Between regulatory query and response there is Design Space. In that space is our comparability protocol
Real world evidence pharmaceutical industry-plPeter Le
油
This document discusses the challenges and opportunities of real-world evidence (RWE) in the pharmaceutical industry. It notes that while RWE from real-world data can help improve drug development, operations, and decision-making, there are also challenges to overcome. These include issues with data accessibility, analysis capacity, and balancing limited resources. However, RWE also presents opportunities to increase value, understand effectiveness beyond clinical trials, and gain business insights. Overall, RWE brings significant opportunities if pharmaceutical companies can address solvable challenges through leadership, governance, and transformation.
The document provides an overview of clinical study protocols, including their purpose, key components, and importance. It describes the various sections of a protocol, such as the background and objectives, study design, subject selection criteria, study procedures, safety and efficacy assessments, and data handling. Maintaining adherence to the protocol is important to ensure the safety of participants and integrity of the clinical trial.
Setting up of new pharmacovigilance centresPriti Gupta
油
Cure & Care Pharma proposes establishing a Pharmacovigilance Centre to monitor drug safety. The centre would be approved by regulatory authorities and function to collect, analyze and communicate information about adverse drug reactions and risks. The proposal outlines the need for pharmacovigilance due to increasing drug availability and irrational practices. It describes the centre's scope, reporting processes, infrastructure needs and budget to effectively oversee post-marketing drug safety.
Walter King is a seasoned senior R&D executive with over 30 years of experience in medical device and diagnostic product development. He has a proven track record of successfully directing projects from research through product launch on time and on budget. Key accomplishments include overseeing development of personalized diagnostic tests and medical devices that were paramount in the sale of two companies. He possesses strong leadership skills and experience managing multi-disciplinary teams across major companies.
Delivering real world evidence to demonstrate product safety and valueKishan Patel, MBA
油
This document discusses how observational research and patient registries can provide real-world evidence on product safety and effectiveness. It outlines Quintiles' capabilities in this area, including experience conducting 195 patient registries and observational studies involving over 9 million patients. Quintiles claims it can help companies demonstrate products' performance in various populations and support regulatory and coverage decisions through generating real-world evidence.
This document summarizes the professional experience and qualifications of Byounist Shuler. She has over 20 years of experience in the pharmaceutical and biopharmaceutical industries, specializing in areas like regulatory compliance, quality assurance, clinical research coordination, and advertising/promotional review. She has extensive knowledge of FDA regulations and guidelines. Her background demonstrates a proven ability to successfully manage projects and ensure compliance.
Vanessa Tasso has over 15 years of experience in healthcare and aerospace operations, specializing in clinical affairs, regulatory compliance, and marketing. She has a proven track record of optimizing business processes, managing clinical trials, gaining regulatory approvals, raising funds, and commercializing new medical technologies. Notable achievements include accelerating patient enrollment in a clinical trial by 500% ahead of schedule and raising $44M for an IPO. She is skilled in developing compliant documentation, navigating international trials, and creating compelling marketing materials to promote new treatments.
This document summarizes an event for innovations in clinical data management taking place from October 27-28, 2016 in Alexandria, Virginia. It will feature over 20 presentations from industry leaders on utilizing mobile technologies, wearable devices, risk-based monitoring, and electronic health records to improve efficiencies in clinical data management. Topics will include FDA compliance expectations, patient-centric data collection, data quality best practices, and preparing for FDA inspections.
Wendelyn Bradley is a clinical informatics leader with over 30 years of experience in healthcare IT, operations, and consulting. She currently serves as an Epic Organizational Readiness Lead at Scripps Health, helping to implement a $0.5 billion integrated IT system. She has a background in nursing, medical informatics, and holds credentials including BSN, MA, MS in Medical Informatics.
This document provides a summary of Ronny Fryar's career experience and qualifications for an executive level healthcare position. It outlines his experience as a Medical Technologist, Laboratory Manager, and Healthcare Administrator/Director over 30 years in the US Army, including roles as Director of Allied Health and Ancillary Services overseeing quality, efficiency and patient experience across multiple facilities, Executive Director of Primary Care Clinics, and Director of the US Army Blood Program and other blood banking facilities, demonstrating experience leading large budgets and staff. It also lists his education in Biology and Medical Technology and board certifications in Blood Banking and as a Medical Technologist.
Brenda Lockler has over 16 years of experience in healthcare IT and is currently a senior systems engineer at CHI St. Luke's Health. She has extensive experience providing project management and business analysis for clinical applications such as Epic Ambulatory, Phoenix, and ClinDoc. Lockler also has experience developing clinical workflows, building reports, and implementing various healthcare systems. She is a registered nurse with additional certifications in project management and various electronic health record systems.
Cynthia Cadwell has over 30 years of experience in nursing and healthcare quality improvement. She currently works as a nurse practitioner providing clinical care and case management to injured workers. Her background includes roles in healthcare consulting, clinical research, quality improvement, and executive leadership positions at hospitals and healthcare companies. She has extensive experience designing and implementing programs to improve clinical outcomes and reduce costs.
The document is a resume for Kim Bonett summarizing her experience and expertise. She has over 15 years of experience in information technology, specializing in health IT. Her experience includes clinical data analytics, programming, nursing, education, and she is a subject matter expert in pathology, radiology, diagnostic imaging and billing. She has extensive experience in project management, requirements analysis, application development, testing and clinical system support.
Lynne E. Becker is seeking a senior level position in corporate project research. She has over 10 years of experience managing multi-site clinical research projects, including experience in protocol development, site selection and training, patient recruitment and retention, and ensuring regulatory compliance. She is skilled in data analysis, database management, and using technology like telemedicine to efficiently achieve project goals. Her background includes managing both domestic and international clinical trials with budgets in the millions of dollars.
Lynne E. Becker is seeking a senior level position in corporate project research. She has over 10 years of experience managing multi-site clinical research projects, including experience in protocol development, site selection and training, patient recruitment, and ensuring regulatory compliance. She is skilled in data analysis, database management, and using technology like telemedicine to efficiently achieve project goals.
This document provides biographical and professional information about Jeffrey Halbstein-Harris, including his expertise in clinical informatics and population health management. It outlines his mission, work experience spanning over 30 years in healthcare IT, accomplishments, skills, education and references.
Four strategies to upgrade clinical trial quality in this computerized world ...Pubrica
油
Biostatistics Services is important for collecting, reviewing, presenting, and interpreting data in clinical research.
Applications of clinical biostatistics services are in different areas, such as epidemiology, clinical trials, population genetics, the biology of structures, and more.
Reference : https://pubrica.com/services/research-services/biostatistics-and-statistical-programming-services/
Continue Reading: http://bit.ly/36nwtcs
Why Pubrica?
When you order our services, Plagiarism free|onTime|outstanding customer support|Unlimited Revisions support|High-quality Subject Matter Experts.
Contact us :
Web:https://pubrica.com/
Blog:https://pubrica.com/academy/
Email:sales@pubrica.com
WhatsApp : +91 9884350006
United Kingdom: +44- 74248 10299
Integrate RWE into clinical developmentIMSHealthRWES
油
With greater application of RWE throughout the pharmaceutical
lifecycle, learnings are emerging that offer guidance for
approaches to derive the maximum value. This article captures
the authors experience at a leading international biotech, with
insights for smoothing RWE assimilation into clinical
development and realizing the benefits it brings.
Vivian Spicer is a senior healthcare executive with over 30 years of experience in healthcare information systems, project management, and strategic leadership. She has extensive expertise in managing complex system implementations, establishing project management frameworks, and aligning IT solutions to business goals. Her background includes roles as a director of application systems, program manager, and project executive for large healthcare organizations.
The professional has over 10 years of experience as a clinical researcher and medical writer specializing in managing multidisciplinary teams and regulatory submissions. They have experience in clinical workflows including assays, treatments, and data analysis. The professional has held several leadership roles in healthcare and life sciences companies focused on clinical research, telehealth, biomedical informatics, and network security.
The document is a resume for Paul Andresen. It summarizes his career in medical laboratory management and embryology, which spans over 25 years. He has held several leadership roles, including Laboratory Supervisor, Technical Laboratory Director, and Embryology Director. His experiences include managing laboratories, developing procedures, ensuring regulatory compliance, improving success rates, and providing training. He has a bachelor's degree in biology and chemistry and is a board certified embryology laboratory director.
The document is a resume for Paul Andresen. It summarizes his career in medical laboratory management and embryology, which spans over 25 years. He has held several leadership roles, including Laboratory Supervisor, Technical Laboratory Director, and Embryology Director. His experiences include managing laboratories, developing procedures, ensuring regulatory compliance, improving success rates, and providing training. He has a bachelor's degree in biology and chemistry and is a board certified embryology laboratory director.
The document is a resume for Alan S. Dow, an experienced healthcare administrator. He has over 15 years of experience managing clinical operations and quality improvement programs for neurology and neurosurgery departments. His experience includes operational management, strategic planning, process improvement, financial management, and ensuring compliance. He is skilled in identifying and implementing methodologies to improve operations and quality of care.
1. 4523 Cather Avenue ROBERT E. PARSON 858.357.6491
San Diego, CA 92122 robert.e.parson@gmail.com
EXECUTIVE LEADERSHIP
A dedicated leader with a proven track record of guiding products from concept to commercialization.
Experienced in developing and manufacturing products, ensuring quality and reliability. Played integral roles by
holding key membership positions on corporate FDA and global regulatory submission teams, enabling clearance
of hundreds of medical and IVD devices. Though leadership and decisiveness, implemented successful disease
management programs. Adept at use of finance and actuarial techniques combined with excellent communication,
team building, international business and program management skills.
CORE COMPETENCIES
Strategic Planning Consulting Project Leadership Program Management
Regulatory Affairs Pharmaco-economics Biometrics Process Engineering
International Business Quality Control Process Improvement Risk Management
Clinical Research Change Management Health Care Advocacy Disease Care Management
EDUCATION
UNIVERSITY OF CALIFORNIA, San Diego, CA
Masters of Advanced Studies: Leadership of Healthcare Organizations
Independent Study Project: A Comprehensive Review of Diabetes Chronic Disease Management Programs for the
Purpose of Identifying Features to Improving Outcomes, Reducing Cost and Maintaining Quality
Internships: San Diego Hospice Center and Scripps Whittier Diabetes Program
ROCHESTER INSTITUTE OF TECHNOLOGY, Rochester, NY
Masters of Science: Applied Statistics (Biostatistics)
Thesis Topic: Evaluation of the Monroe County Healthcare Library Network Statistical Education and Information
Systems Planning
PURDUE UNIVERSITY, West Lafayette, IN
Bachelors of Science: Biochemistry
Minor: Mathematics/Statistics
HIGHLIGHTS OF SKILLS & ACCOMPLISHMENTS
Pharmaco-economics & Outcomes Research
Developed Markov Models for prostate cancer screening programs using Tandem tPSA and fPSA/tPSA
Ratio in support of Managed Care decision-making to provide tests in patient care protocols.
Authored cost-effectiveness/budget impact models and analyses for immunological fecal occult blood tests
used in support of international, national healthcare system reimbursement and funding decision-making.
Coordinated and direction to a global staff of 30 marketing and sales professionals preparing national and
regional healthcare system tender offers that incorporated budget impact analyses and comparative
performance analysis with technology assessment assessments.
Regulatory Affairs
Directed and partnered across R&D, Clincal, Marketing, Business Development and Sales groups the
integration of required regulatory guidance into product regulatory approval and registration strategy.
Enabled global cost analysis and reporting by implementing a budgeting/cost tracking system that
resulted in improvements in tracking expenditures for international registration and labeling changes.
Facilitated introduction new product and product improvements by managing all aspects of approval
2. process for large, diverse global organization.
ROBERT E. PARSON - PAGE 2 OF 4
858.357.6491 - robert.e.parson@gmail.com
Clinical Operations
Established Global Clinical Affairs organization for Inverness Medical Innovations to support clinical
programs. Transformed group of small, disjointed staffs with varying levels of education and experience
into efficient global network.
Integrated Electronic Data Capture (EDC) with Clinical Study Information procedures and Clinical
Information Management System (CIMS).
Successfully initiated international clinical study / trial programs for post-registration studies that allowed
regional organizations access to clinical and EDC resources via Centers of Clinical Excellence.
Biostatistics
Evaluated new medical diagnostic assays for FDA and global approvals, clinical trial protocols, statistical
plans, and detailed submissions for regulatory clearance.
Oversaw completion of 300+ 510K and 4 PMA FDA submissions and supplements, plus corresponding EU,
Japanese, and Australian submissions.
Presented PSA (prostate specific antigen) screening claim to FDA PMA panel meeting. Wrote SAP and
supported 6,770 patient studies with statistical analysis. Wrote CSR for study.
Evaluated clinical designs for efficacy, statistical power, and assumption verification and identify strengths
and weaknesses of clinical study using simulation methods. Designed SAP for Tandem tPSA, fPSA, CA125,
CA19.9, Ostase, AccuTnI Troponin assay, and many others (Hemoccult Sensa, ICT, NS-Plus, Blood
Chemistries).
Clinical Data Management
Performed strategic systems planning combining electronic data capture (EDC) and clinical trial
management system (CTMS) along with document management, registration dBase, on-line training
systems, electronic medical device reporting (eMDR), and SharePoint systems implementation for
international project management.
Devised and implemented organizational, procedural, and processing changes to achieve regulatory
compliance.
PROFESSIONAL EXPERIENCE
ALERE INC. (formerly Inverness Medical Innovations), San Diego, CA
Alere is comprised of 18 leading diagnostic and health management companies and is the second-largest health management
provider in United States producing revenue of $2.1 billion. Employees span the globe.
Vice President, Pharmacoeconomics & Outcomes Research 2010-2011
Managed generation of $50 million in revenue from oncology products (NMP22 (BladderChek, NS-Plus iFOBT
joint distribution between Otsuka Electronics Corporation and Alfresa Pharmaceutical Corporation). Drove
progress of new products and oversaw international tenders program, regulatory clinical studies in US, China, and
Canada, and regulatory submissions.
Collaborated with leaders in global organization to devise strategy to obtain funding to implement new
technology in countries with National Healthcare Systems.
Created strategy for global distribution of the NS-Plus i-FOBT assay system, obtaining agreement of all 3
distribution partners (Alere, Alfresa, and Otsuka).
Incorporated efficiency and cost effectiveness simulation models to compare costs in connection with
staffing resources, laboratory space, reagent costs, laboratory data, and information processing into
marketing and sales of new technology.
3. Planned and prepared for efficient integration of outcomes studies into analysis of laboratory technology
under evaluation of international healthcare organizations.
4. ROBERT E. PARSON - PAGE 3 OF 4
858.357.6491 - robert.e.parson@gmail.com
INVERNESS MEDICAL INNOVATIONS (formerly Biosite and now Alere, Inc.), San Diego, CA
International medical device manufacturer with product portfolio spanning cardiovascular, drugs of abuse, women's health,
oncology, and infectious disease areas. Led market in rapid point-of-care diagnostic and clinical testing. With 11,900
employees worldwide, produced $2.1 billion in revenue.
Vice President, Global Clinical & Regulatory Affairs 2008-2010
Directed global clinical and regulatory affairs for 55 companies and distributors for 1,600 products enabling
detection and management of autoimmune diseases, infectious and enteric diseases, sexually-transmitted diseases,
colorectal and bladder cancers, and cardiac risk. Supervised team of 15 senior-level managers and oversaw global
clinical staff of 225. Managed annual budget of $24 million.
Established Global Clinical Affairs organization to support companys clinical programs, which was
comprised of 75 employees worldwide.
Standardized training programs and training schedules for all staff, transforming previously disorganized
programs into unified and efficient programs.
Provided regional organizations with access to clinical and EDC resources by using Centers of Clinical
Excellence.
Streamlined processes for effective and timely medical devise reporting, improving turnaround from 12
weeks to 4 weeks.
Formed Medical Affairs Team to handle off-label customer requests.
Instituted additional regulatory guidance into product regulatory approval and registration strategy,
working in conjunction with regulatory management and clinical teams.
BIOSITE INC., San Diego, CA
$300 million company renown for rapid, high-capacity antibody development, enabling high throughput screening of potential
diagnostic markers and cost-efficient development of high affinity antibodies for use in commercialized products.
Senior Director, Clinical & Medical Affairs Group 2006-2008
Advanced new product regulatory clinical studies, post approval studies, and pre-clinical studies and evaluations.
Developed database, validation, and reporting systems for clinical and R&D. Supervised 2 biostatisticians and
clinical data management staff of 4.
Revised standard operating procedures (SOPs) to maintain regulatory compliance and to increase focus on
corporate objectives.
Successfully completed 9 clinical study statistical analysis plans, analyses, and reports that were integral to
FDA and EU (CE marker) submissions.
Trained staff on statistical methodologies, sample size calculations, and preparation of statistical analysis
plans used for pre-clinical, clinical, and post-clinical (outcomes) studies for cardiovascular point-of-care
assays (Troponin, CKMP, BNP), pre-independent development evaluations, and production registration
applications.
Developed multi-parameter (biomarkers, patient demographics, pathology) logistic regression models
approach to evaluate various biomarker assays in plasma to be used on Triage point-of-care assay
platform, which led to 3-biomarker panel for diagnosis of community-acquired sepsis in patients
presenting in emergency rooms.
BECKMAN COULTER INC., San Diego, CA
Company develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing
performed in hospitals and critical care settings.
Senior Staff Biostatistician, Regulatory & Clinical Affairs 1996-2006
Supported product development, commercialization, troubleshooting and manufacturing of diagnostic assays,
instrumentation and information systems. Assessed and mitigated risk.
5. ROBERT E. PARSON - PAGE 4 OF 4
858.357.6491 - robert.e.parson@gmail.com
HYBRITECH INCORPORATED (Eli Lilly & Co.), San Diego, CA
Biotechnology Company that developed and marketed monoclonal antibodies used to make diagnostic and medical monitoring
tests to identify various infectious, viral and cancer-related diseases, infertility, allergies, and pregnancy.
Director, Biostatistics, Clinical & Regulatory Affairs 1990-1996
Oversaw biostatistics, clinical data management, and managed care planning. Supervised clinical and regulatory
staffs. Managed manufacturing, quality control, research, and development. Created health economic models.
CERTIFICATIONS
ASQ Certified Reliability Engineer, ASQ Certified Quality Engineer and Certified Healthcare Executive
PROFESSIONAL AFFILIATIONS
International Society for Pharmaco-economics and Outcomes Research
Organization Memberships Drug Information Association
American Society for Quality Senior Member Status
Clinical Laboratory Management Association
American Association for Clinical Chemistry
American Statistical Association
Society for Controlled Clinical Trials
Society for Medical Decision Making
Clinical Data Management Association
COMPUTER SKILLS
Statistical Analysis System (SAS),RS-1, Data TreeAge Software, Medcalc, nQuery and PASS Sample Size Estimates,
Microsoft Word, Excel, Project, Visio, SQL Database, Crystal Ball